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Background: We evaluated the doseeresponse of umeclidinium (UMEC; a long-acting musca-
rinic antagonist) combined with fluticasone furoate (FF; an inhaled corticosteroid [ICS]) in
patients with asthma.
Methods: In a double-blind, three-period crossover study, 421 subjects (symptomatic on ICS),
were randomized to a sequence of three of seven treatments: FF 100 mcg alone, FF 100 mcg
combined with UMEC (15.6, 31.25, 62.5, 125, or 250 mcg), or vilanterol 25 mcg (a long-acting
b-agonist), inhaled once-daily for 14 days (12e14-day washout). Trough forced expiratory vol-
ume in one second (FEV1), peak expiratory flow (PEF), and safety were assessed.
Results: Period baseline was a significant covariate, indicating a potential carryover effect be-
tween treatment periods. Across all treatment periods, trough FEV1 improved with FF/UMEC
125 and 250 versus FF (treatment difference 0.055 L [both doses]; p Z 0.018). FF/UMEC
increased morning (15.9e22.9 L/min) and evening (16.2e28.8 L/min) PEF versus FF. As in-
tended assessments were confounded, post hoc Period 1 data analyses were performed,
demonstrating significant increases in trough FEV1 with FF/UMEC 31.25, 62.5, and 250 versus
FF. Trough FEV1 improvements with FF/UMEC were greater in subjects with fixed (0.095
e0.304 L) versus non-fixed (0.084 to 0.041 L) obstruction. The incidence of on-treatment
adverse events was 13e25% across groups. No treatment-related effects on laboratory
parameters were reported., confidence interval; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; ECG,
atory volume in one second; FF, fluticasone furoate; FVC, forced vital capacity; GCP, Good Clinical
ICH, International Conference on Harmonisation; ITT, intent-to-treat; LABA, long-acting b-agonist;
ist; LS, least squares; MedDRA, Medical Dictionary for Regulatory Activities; PEF, peak expiratory flow;
ard deviation; SE, standard error; UMEC, umeclidinium bromide; VI, vilanterol.
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Fluticasone furoate/umeclidinium in patients with asthma 55Conclusion: FF/UMEC may be a viable treatment for patients with asthma symptomatic on ICS;
benefit may be most prominent in those with fixed obstruction. The carryover effect suggests
future UMEC studies should use an alternative design.
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Asthma is a chronic inflammatory disorder of the airways
with variable airflow obstruction that is often reversible but
may be incomplete in some patients. Despite the avail-
ability of current treatment options for asthma, many
patients remain symptomatic and may experience asthma
exacerbations [1]. Alternative treatments are therefore
needed.
Although parasympathetic nervous system dysfunction is
well established in asthma [2e4], long-acting muscarinic
antagonists (LAMAs) have been used predominantly in
treating chronic obstructive pulmonary disease (COPD) [5].
There is a growing body of evidence to support the efficacy
of tiotropium in asthma [6,7], leading to inclusion of these
data in current asthma guidelines [8]. Whilst the guidelines
recognize the potential for tiotropium as an additional
therapeutic option in patients with severe asthma and
persistent airflow limitation, it is not a recommended
treatment and no LAMA has received regulatory approval
for this indication.
The objective of this study was to evaluate the
doseeresponse, efficacy, and safety of the once-daily LAMA
umeclidinium bromide (UMEC), when combined with fluti-
casone furoate (FF, an inhaled corticosteroid [ICS]) in adult
patients with asthma who were symptomatic despite
maintenance ICS treatment. UMEC is a quinuclidine deriv-
ative and potent anticholinergic with slow functional
reversibility at the human M3 receptor [9]. UMEC and the
combination of UMEC with the long-acting b2-agonist (LABA)
vilanterol (UMEC/VI) are approved maintenance treatments
for COPD in the US and EU. They are not indicated for
treatment of asthma. FF is in development as a treatment
for both asthma and COPD, and has a longer lung retention
time than fluticasone propionate [10]. FF is well tolerated
in patients with asthma, and has been shown to improve
lung function [11,12].
It was hypothesized that fixed airflow obstruction may
identify subjects with high cholinergic tone and who
therefore may respond favorably to UMEC. The rationale for
this was two-fold. Firstly, airway hyper-responsiveness to
methacholine is a risk factor for the accelerated decline in
lung function with increasing age and the development of
chronic airflow obstruction [13]. Secondly, airflow
obstruction may persist after ICS suppression of hyper-
responsiveness due to inflammation, and this persistent
obstruction could be considered analogous to the chronic
airflow obstruction in COPD where the majority of, if not
all, reversibility can be achieved with an anticholinergic
agent [5]. Both observations suggest that patients with
asthma and fixed airflow obstruction may represent aresponder phenotype with a neural component to their
disease.
Materials and methods
Study design
This was a randomized, double-blind, three-period cross-
over, incomplete-block study (GSK study ILA115938; Clin-
icalTrials.gov identifier NCT01573624 [April 2012eFebruary
2013]), conducted at 33 centers across Argentina, Chile,
Russia, Thailand, and the US.
Patients meeting inclusion criteria at screening (Visit 1)
entered a 2-week, open-label run-in period, during which
reversibility testing to ipratropium bromide was performed
(Visit 2). Eligible subjects were randomized to a sequence of
three of seven treatments (five FF/UMEC combination doses,
FF alone, and FF/VI as active comparator), separated by
12e14-day washout periods. During run-in and washout
periods, subjects self-administered open-label, once-daily
FF 100 mcg in the morning via dry powder inhaler (DPI).
During each 14-day treatment period there were three
visits, one at the beginning (first dose) and two at the end
of the treatment period (the last day of dosing and the
following day). A follow-up visit was performed approxi-
mately 7 days following Treatment Period 3. All subjects
had albuterol/salbutamol (herein referred to as albuterol)
provided as rescue medication.
The study was approved by a national or regional Ethics
Committee/Institutional Review Board in each country, and
in accordance with the International Conference on Har-
monisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use Good Clinical Practice (ICH-
GCP) guidelines, all applicable subject privacy re-
quirements and ethical principles outlined in the Declara-
tion of Helsinki, 2008 [14,15]. Written, informed consent
was obtained from each subject before study procedures
were performed.
Patients
Eligible patients: were 18 years of age; had an asthma
diagnosis for 6 months before Visit 1 (as defined by the
National Institutes of Health [16]); had a pre-
bronchodilator forced expiratory volume in one second
(FEV1) of 40e80% predicted at Visit 1 (based on National
Health and Nutrition Examination Survey III [17,18]); had
12% and 0.200 L reversibility to albuterol at Visit 1;
required regular controller therapy (ICS alone or combined
with a LABA or leukotriene modifier) and had received a
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taken a stable ICS dose for 4 weeks before Visit 1.
Subjects were randomized to treatment if they: exhibi-
ted a pre-dose FEV1 of 40e80% predicted at Visit 3; had
reported asthma symptoms; and recorded use of FF
100 mcg on 4 of the last 7 consecutive days of the run-in
period. Subject stratification by age (18e29, 30e49, and
50 years) ensured adequate exposure in each age group.
Patients were excluded if they: were of childbearing
potential (unless practicing acceptable birth control
methods); had a history of life-threatening asthma; had
experienced a severe asthma exacerbation within the 4
weeks before Visit 1; had a current respiratory infection/
disease, viral hepatitis, human immunodeficiency virus,
visual evidence of candidiasis, a condition preventing
anticholinergic medication use (narrow-angle glaucoma,
prostatic hypertrophy, or bladder outlet obstruction that
would pose a safety risk with the use of an inhaled anti-
cholinergic), or a history of alcohol/substance abuse; were
current smokers with a history of 10 pack-years; had a
milk protein allergy or an immediate/delayed hypersensi-
tivity to any b-agonist, sympathomimetic, or any intranasal,
inhaled or systemic corticosteroid therapy; were unable to
comply with the study protocol; or had received prescrip-
tion or over-the-counter medication that would affect the
course of asthma or interact with the study drug. Further
details of prohibited concomitant medications are provided
in the Supplementary File 1 and Supplementary Table 1.
Procedures
Subjects were randomized to a sequence of three of seven
treatments: FF 100 mcg alone, and combined with UMEC at
doses of 15.6, 31.25, 62.5, 125, and 250 mcg, and VI 25 mcg
(Fig. 1). All treatments were self-administered once daily
(in the morning) via a dual-strip DPI.
Subjects were randomized using SAS-generated codes
imported into a validated computerized system (Randall
Version 2.5, GlaxoSmithKline). The Registration and Medi-
cation Ordering System was used to register and randomize
subjects.
Outcomes and assessments
Efficacy endpoints
The primary efficacy endpoint was change from baseline in
trough FEV1 on Day 15 of each treatment period. Baseline
was pre-dose FEV1 on Day 1; trough FEV1 was obtained 24 h
after morning dosing on Day 14. Mean change from baseline
in morning and evening peak expiratory flow (PEF) and
rescue albuterol use were secondary efficacy endpoints;
symptom-free days and mean change from baseline to Day
14 in trough FEV1 were also assessed. Spirometry assess-
ments were performed at all visits (screening, pre-
randomization, and Days 1, 14, and 15 of each treatment
period). PEF, asthma symptoms, and rescue albuterol use
were recorded using electronic diaries.
Exploratory analyses
Exploratory analyses examined possible predictors of
change from baseline in trough FEV1, including age, sex,body mass index, asthma duration, screening FEV1 and
FEV1/forced vital capacity (FVC) ratio, albuterol revers-
ibility, ipratropium reversibility, heart rate, systolic and
diastolic blood pressure, and the asthma control test [19].
Safety
Safety assessments included adverse events (AEs), serious
AEs (SAEs), severe asthma exacerbations (deterioration of
asthma requiring systemic corticosteroid use [oral or in-
jection] for 3 days or an in-patient hospitalization/
emergency department visit due to asthma that required
systemic corticosteroids), and oral candidiasis. Vital signs,
clinical chemistry parameters, hematology parameters,
and 12-lead electrocardiograms (ECGs) were evaluated. AEs
were coded using Medical Dictionary for Regulatory Activ-
ities (MedDRA) terms.
Statistical analyses
The study design provided 92% power to detect a 0.150 L
difference in FEV1 between any active combination treat-
ments (FF/UMEC or FF/VI) and FF. It was assumed that
a Z 0.05, that the within-patient standard deviation of
FEV1 was 0.375 L, and that testing was two-sided. Approx-
imately 420 subjects were randomized to ensure that 336
completed all three double-blind treatment periods.
Analyses were conducted in the intent-to-treat popula-
tion (subjects randomized to treatment and receiving 1
dose of study medication). Only subjects who had taken FF
and FF/UMEC were included in doseeresponse analyses
(using linear and non-linear mixed-effects modeling) for the
primary endpoint. Other efficacy endpoints were analyzed
using mixed-model methods. Linear regression models
assessed possible predictors of change from baseline in
trough FEV1. Descriptive statistics summarized safety data.
Multiplicity was controlled with a step-down closed
testing procedure for the primary efficacy endpoint with
the following comparisons: FF/UMEC 250 versus FF, then
FF/UMEC 125, 62.5, 31.25, and 15.6 versus FF.
All analyses were performed via SAS Version 9 or
NONMEM Version 7.1.
Results
Subjects
Of the 706 patients screened, 421 were randomized to
treatment (Fig. 1; Russian Federation, n Z 146 [35%];
Argentina, n Z 106 [25%]; Chile, n Z 74 [18%]; US, n Z 59
[14%]; Thailand, nZ 36 [9%]). The most common reason for
withdrawal was lack of efficacy (n Z 50; 12%). Twelve
subjects (3%) withdrew due to meeting protocol-defined
stopping criteria (ECG abnormalities, n Z 10 [2%]; liver
function test abnormality, n Z 1 [<1%]; sub-reason not
reported, n Z 1 [<1%]). The incidence of withdrawals
across FF/UMEC treatment and washout periods was low
(2e8%), and did not appear dose related. The incidence of
withdrawals relating to AEs was also low (n Z 8, 2%).
Most subjects were White, female, and had a diagnosis
of asthma for 10 years (Table 1). Subjects had moderate
impairment in airflow obstruction (mean FEV1 62.31%
(N = 523)
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Figure 1 Subject disposition and CONSORT flow chart. FF, fluticasone furoate; ITT, intent-to-treat; UMEC, umeclidinium;
VI, vilanterol.
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ipratropium. In total, 404 (96%) of subjects reported ICS use
prior to the run-in period, with 181 (43%) reporting ICS plus
LABA use in fixed-dose combination or single inhalers. At
Visit 1 (screening), the mean pre-albuterol FEV1 was
1.847 L, while at Visit 2 (during run-in), the mean pre-
ipratropium FEV1 was 1.952 L (Supplementary Fig. s1).Efficacy outcomes
All treatment periods
The mean change from baseline in trough FEV1 on Day 15
was greater with all FF/UMEC doses (0.141e0.214 L) and
FF/VI (0.200 L), compared with FF (0.087 L). The least
squares (LS) mean change was statistically significantlydifferent for FF/UMEC 125 and 250 (both 0.055 L;
p Z 0.018), and FF/VI (0.078 L; p < 0.001) compared with
FF (Supplementary Table 2, Fig. 2). Doseeresponse
analyses indicated the slope-intercept on log-dose model
was the most appropriate model evaluated, with a good
agreement between the observed and predicted trough
FEV1 change from baseline. When the final model was used
to predict trough FEV1 change from baseline, FF/UMEC 125
and 250 produced statistically significant effects compared
with FF (Fig. 3).
The doseeresponse modeling showed that the baseline
for each treatment period (period baseline) was a statisti-
cally significant covariate, with an interaction between
period baseline and treatment identified in the mixed-
effects model (p Z 0.057). Variability was observed in
period baseline, with a median difference of 0.003 to
Figure 2 Adjusted mean differences from FF 100 (95% CI)
in change from baseline in trough FEV1 (L) on Day 15
(ITT population). *p < 0.05; **p < 0.001. CI, confidence
interval; FEV1, forced expiratory volume in one second; FF,
fluticasone furoate; ITT, intent-to-treat; UMEC, umeclidinium;
VI, vilanterol.
Figure 3 Distribution of change from baseline in trough
FEV1 adjusted for FF 100 mcg alone by dose of UMEC com-
bined with FF 100 mcg in the ITT population. FEV1, forced
expiratory volume in one second; FF, fluticasone furoate; ITT,
intent-to-treat; UMEC, umeclidinium.
Table 1 Subject demographics and baseline
characteristics.
Demographic Total (N Z 421)
Sex, n (%)
Female 289 (69)
Male 132 (31)
Mean age, years (SD) 47.5 (13.84)
Age group, n (%)
18e29 years 54 (13)
30e49 years 186 (44)
50 years 181 (43)
Ethnicity
White 367 (87)
Asian 36 (9)
African-American/African heritage 18 (4)
Asthma duration
<1 year 7 (2)
1 yeare<5 years 54 (13)
1 yeare<5 years 71 (17)
10 years 289 (69)
Smoking status
Non-smoker 325 (77)
Former smoker 96 (23)
Mean pre-albuterol FEV1, L (SD) n Z 417
1.847 (0.5288)
Mean pre-albuterol FEV1,
% predicted (SD)
n Z 417
62.31 (10.321)
Mean post-albuterol FEV1, L (SD) n Z 419
2.391 (0.6837)
Mean post-albuterol FEV1,
% predicted (SD)
n Z 419
80.63 (13.019)
Mean pre-ipratropium FEV1, L (SD) n Z 419
1.952 (0.5882)
Mean post-ipratropium FEV1, L (SD) n Z 419
2.253 (0.6632)
Mean % FEV1 reversibility to
albuterol (SD)
n Z 417
30.15 (14.919)
Mean % FEV1 reversibility to
ipratropium (SD)
n Z 419
16.71 (14.191)
FEV1, forced expiratory volume in one second; SD, standard
deviation.
58 L.A. Lee et al.0.030 L across treatment groups. Over Washout Period 1
(where subjects received open-label FF) the effects of VI on
morning and evening PEF declined (17.99 L/min and
25.80 L/min, respectively), while those of UMEC were
generally similar or modestly reduced (10.06 to 2.19 L/
min, 12.79 to 1.20 L/min). These findings suggest a
maintained effect of UMEC over the washout period, which
invalidates the crossover study design, leaving Treatment
Period 1 data available for analysis.
Trough FEV1: Treatment Period 1
Post hoc analyses of Treatment Period 1 data demonstrated
that the mean change from baseline to Day 15 in trough
FEV1 was greater with all FF/UMEC doses and FF/VI
compared with FF, with robust dose-ordering. The LS mean
change was statistically significantly different for FF/UMEC
31.25 (p Z 0.034), 62.5 (p Z 0.030), 250 (p Z 0.007), andFF/VI (pZ 0.015) compared with FF (Supplementary Table
3, Supplementary Fig. s1). The slope-intercept on log-dose
model remained most appropriate to describe the
doseeresponse, with the mean model-predicted trough
FEV1 change from baseline >0.100 L for all FF/UMEC doses
compared with FF. A statistically significant effect was
maintained only with FF/UMEC 125 (0.158 L; 95% confi-
dence interval [CI], 0.007e0.312) and 250 (0.176 L; 95% CI,
0.015e0.347) doses.
Other efficacy outcomes
Statistically significant increases from baseline in morning
and evening PEF were observed for all FF/UMEC doses and
for FF/VI compared with FF (all p < 0.001; Supplementary
Table 4). Furthermore, a statistically significant reduction
in on-treatment rescue albuterol use was observed with FF/
UMEC 15.6, 125, and 250 (all p < 0.05), as well as FF/VI
(p < 0.001), compared with FF. However, changes in the
percentage of rescue-free days and symptom-free days
were not statistically significant when compared with FF
(Supplementary Table 5). In comparison with FF, the LS
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greater with all FF/UMEC treatments (0.118e0.157 L
[treatment difference vs FF 0.041e0.079 L]; all p  0.014,
except for FF/UMEC 31.25 [0.118 L; treatment difference vs
FF 0.041 L; p Z 0.068]) and FF/VI (0.163 L; treatment
difference vs FF 0.085 L; p < 0.001).
Exploratory analyses
Multiple statistically significant predictors of trough FEV1
response were identified in linear regression models
(Supplementary Table 6a). The data indicate that subjects
who showed greater reversibility to short-acting broncho-
dilators were more likely to respond to treatment, exhib-
iting larger increases in trough FEV1. The Pearson
correlation coefficients were low (for overall data and by
treatment; range: 0.242 to 0.362) and the data did not
indicate any clinically-relevant predictors of response.
When the significant predictors from the linear regression
models were included in multiple regression models (over-
all and by treatment), few significant predictors were
identified and the model multiple correlation coefficients
were low (overall, R2Z 0.224 [Supplementary Table 6b]; by
treatment, all R2 < 0.3). Based on these findings, post-
albuterol FEV1/FVC ratio was carried forward into a post
hoc inferential analysis.
A post hoc analysis was performed to assess if there was
an effect of post-bronchodilator FEV1/FVC ratio on the
change from baseline in trough FEV1 on Day 15 of each
treatment period. The analysis was stratified such that
subjects were considered to have fixed obstruction if theyFigure 4 Adjusted mean differences from FF 100 (95% CI) in ch
fixed obstruction versus non-fixed obstruction in the primary a
p < 0.05; **p < 0.001. CI, confidence interval; FEV1, forced
UMEC, umeclidinium.had a post-albuterol FEV1/FVC ratio 0.7, and non-fixed
obstruction if their post-albuterol FEV1/FVC ratio was
>0.7 at screening. Overall (all treatment periods), the
effect of UMEC-containing treatments on trough FEV1 on
Day 15 was greater in subjects with fixed obstruction
(difference vs FF: 0.035e0.104 L) than non-fixed obstruc-
tion (difference vs FF: 0.002 to 0.031 L) (Fig. 4). These
effects were statistically significant in subjects with fixed
obstruction receiving FF/UMEC 125 (0.078 L; p Z 0.030),
FF/UMEC 250 (0.104 L; p Z 0.003), and FF/VI (0.102 L;
pZ 0.003). In the Treatment Period 1 data analyses where
data were devoid of a carryover effect, the effect of UMEC-
containing treatments on trough FEV1 on Day 15 was also
greater in subjects with fixed obstruction (difference vs FF:
0.095e0.304 L) than non-fixed obstruction (difference vs
FF: 0.084 to 0.041 L) (Fig. 4).
Safety
The incidence of on-treatment AEs was 13e25% across
treatment groups, with the highest incidence reported for
FF/VI (25%). Headache occurred in 2e4% of subjects
receiving FF/UMEC, 2% of subjects receiving FF, and 3% of
subjects receiving FF/VI, and was the only AE reported in
3% of subjects in any treatment arm (Table 2). Abnormal
product taste that was considered treatment-related
occurred in 2% of subjects in each of the FF/UMEC 31.25
and 125 treatment groups, and was the only treatment-
related AE occurring in 2% of subjects in any treatment
arm. Few subjects (2%) experienced an on-treatment AE
leading to study withdrawal and there were no fatal AEs.ange from baseline in trough FEV1 on Day 15 in subjects with
nalysis (all treatment periods) and in Treatment Period 1.
expiratory volume in one second; FF, fluticasone furoate;
Table 2 AEs reported by 1% of subjects on any treatment during the on-treatment period.
AE (MedDRA preferred term) Number (%) of subjects
FF 100 mcg
N Z 187
FF/VI 100/25 mcg
N Z 172
FF 100 mcg/UMEC
15.6 mcg
N Z 183
31.25 mcg
N Z 179
62.5 mcg
N Z 180
125 mcg
N Z 176
250 mcg
N Z 186
Any AE 25 (13) 43 (25) 31 (17) 23 (13) 30 (17) 38 (22) 36 (19)
Headache 3 (2) 6 (3) 4 (2) 2 (1) 5 (3) 4 (2) 7 (4)
Nasopharyngitis 3 (2) 2 (1) 3 (2) 1 (<1) 4 (2) 4 (2) 4 (2)
Rhinitis 2 (1) 2 (1) 3 (2) 0 0 1 (<1) 1 (<1)
Rhinitis allergic 0 4 (2) 1 (<1) 0 1 (<1) 3 (2) 0
Product taste abnormal 0 0 0 3 (2) 0 3 (2) 2 (1)
Upper respiratory tract
infection
1 (<1) 2 (1) 1 (<1) 0 0 1 (<1) 2 (1)
Bronchitis 0 0 3 (2) 0 1 (<1) 1 (<1) 1 (<1)
Dysphonia 0 0 1 (<1) 1 (<1) 0 4 (2) 0
Oral candidiasis 0 2 (1) 2 (1) 0 0 1 (<1) 1 (<1)
Urinary tract infection 0 2 (1) 0 0 2 (1) 2 (1) 0
Cough 0 0 0 2 (1) 1 (<1) 0 2 (1)
Respiratory tract infection 1 (<1) 1 (<1) 2 (1) 1 (<1) 0 0 0
Dysgeusia 0 0 0 0 1 (<1) 2 (1) 1 (<1)
Hypertension 0 0 0 1 (<1) 0 0 3 (2)
Supraventricular
extrasystoles
1 (<1) 0 2 (1) 0 1 (<1) 0 0
Throat irritation 0 0 0 1 (<1) 2 (1) 0 1 (<1)
Toothache 1 (<1) 2 (1) 0 0 0 0 1 (<1)
Nausea 0 0 0 0 0 0 3 (2)
Viral pharyngitis 0 0 0 0 2 (1) 1 (<1) 0
Arthralgia 0 0 0 0 2 (1) 0 0
Influenza 0 0 0 0 0 0 2 (1)
Oral herpes 0 0 2 (1) 0 0 0 0
AE, adverse event; FF, fluticasone furoate; MedDRA, Medical Dictionary for Regulatory Activities; UMEC, umeclidinium; VI, vilanterol.
60 L.A. Lee et al.Two subjects experienced an on-treatment SAE (FF/UMEC
31.25 [asthma exacerbation] and FF/VI [acute cholecys-
titis]), neither considered treatment-related by the
investigator.
Six subjects had on-treatment asthma exacerbations:
one in each of the FF/UMEC 62.5, FF/UMEC 125, FF, and FF/
VI treatment groups and two in the FF/UMEC 31.25 group
(all 1%). Ten subjects had an asthma exacerbation during
a washout period: two from each of the FF/UMEC 125, FF/
UMEC 250, and FF/VI treatment groups and one from the
FF/UMEC 15.6, FF/UMEC 31.25, FF/UMEC 62.5, and FF
groups; all events resolved.
There was no treatment effect on clinical chemistry and
hematology parameters. One subject with a medical history
of hypertension and hepatic steatosis had maximum post-
baseline alanine aminotransferase and aspartate amino-
transferase values more than three times the upper limit of
normal.
Mean systolic/diastolic blood pressure and heart rate
changes were low and similar across treatment groups, with
no statistically significant differences for any vital sign
parameters. Most subjects had normal ECGs at randomiza-
tion (85%) and at any time post-baseline (75e81%). Ten
subjects (2%) withdrew due to meeting ECG stopping
criteria (further details in Supplementary Table 7).Cardiovascular AEs occurred with a low frequency, irre-
spective of treatment (FF/UMEC, <1e2%; FF/VI, 2%; FF,
1%).Discussion
This is the first doseeresponse study evaluating the
bronchodilator effect of UMEC combined with fixed-dose
FF, following once-daily dosing in patients with asthma who
remained symptomatic on ICS treatment. The primary
analysis (all Treatment Periods) showed small increases
from baseline in trough FEV1 for all FF/UMEC treatments
and FF/VI compared with FF alone and only modest dose-
ordering between treatments.
In the overall doseeresponse model, period baseline was
a significant covariate leading to a post hoc analysis of
Treatment Period 1 data alone, unconfounded by prior
treatment. Data from Treatment Period 1 demonstrated
clinically meaningful and statistically significant increases
in trough FEV1 for FF/UMEC doses of 31.25, 62.5, and
250 mcg (0.139e0.182 L) and FF/VI (0.154 L) compared with
FF. This improvement in lung function is consistent with
studies of tiotropium as add-on therapy to ICS or ICS/LABA
treatment in patients with uncontrolled asthma [6,7].
Fluticasone furoate/umeclidinium in patients with asthma 61The period baseline effect may relate to prolonged
pulmonary benefits of UMEC, as measured by spirometry,
which persisted despite the 14-day washout. This indicates
a potential carryover effect of UMEC, which has also been
reported for tiotropium in a study with a similar design in
ICS-treated subjects [7]. Further studies are needed to
validate this finding and to understand the mechanistic
basis of the effect, as prolonged bronchodilation is incon-
sistent with current data on airway M3 receptor antagonism
with LAMAs [20,21]. As crossover studies of UMEC mono-
therapy in patients with COPD [22,23] or patients with mild
asthma [24] showed only a modest period effect that did
not alter study conclusions, it is not clear if the carryover
effect in this study is specific to the study population or
related to concurrent treatment with ICS.
The results of the prospectively identified subgroup
analysis support fixed airflow obstruction as a responder
phenotype for UMEC. In the primary analysis, increases in
trough FEV1 were approximately 0.100 L compared with FF
in subjects with fixed obstruction at the highest FF/UMEC
doses and FF/VI. In Treatment Period 1, unconfounded by a
carryover effect, increases in trough FEV1 were approxi-
mately 0.200 L compared with FF in those subjects at all
but the lowest FF/UMEC dose and with FF/VI. In contrast,
trough FEV1 changes were negligible in subjects with non-
fixed obstruction for both the primary and Treatment
Period 1 analyses. These findings are consistent with post
hoc analyses of the TALC study, which showed that a
decreased FEV1/FVC ratio predicted a positive clinical
response to tiotropium for FEV1 [25]. That almost half of
the subjects in the current study had the responder
phenotype without targeted enrollment criteria, also
observed in a severe asthma study [26], suggests a high
proportion of patients with fixed obstruction participate in
clinical trials of patients with asthma uncontrolled on ICS.
There are several limitations to consider when inter-
preting these data. As the carryover effect was a con-
founding factor, study conclusions are limited to data from
only one of three treatment periods and considering it as a
parallel-arm study with reduced power. The carryover
effect could be addressed with an alternative study design,
or inclusion of longer washout periods. The potential
impact of steroid administration throughout the study on
period baseline could be minimized with a longer run-in
period on ICS alone. Although all FF/UMEC doses appeared
to be well tolerated, with no dose-related AEs or
treatment-related changes in vital signs and clinical labo-
ratory parameters, the study treatment periods were of a
short 2-week duration; longer-term investigation is
required to fully characterize the safety profile of FF/
UMEC.Conclusions
In conclusion, this study suggests that FF/UMEC may be a
well-tolerated and viable treatment for patients with
asthma who are symptomatic on ICS therapy, particularly in
those who have fixed airflow obstruction. Understanding
the doseeresponse has proved difficult due to the shallow
doseeresponse observed in the heterogeneous, largely
unselected population in this study, and may be bettercharacterized in well-defined responder phenotypes.
Although the therapeutic utility of UMEC as a bronchodi-
lator may not be broadly applicable in the asthma popula-
tion, the period baseline effect noted in this study suggests
UMEC has additional therapeutic benefits requiring further
study.
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